CliffBio
small molecule

CLEVIPREX

CLEVIDIPINE

Loss of exclusivityOctober 2031latest FDA-listed patent expiry
CompanyChiesi Usa, Inc. →View the full company profile on CliffBio

Drug detail

Brand nameCLEVIPREX
Active ingredientCLEVIDIPINE
Strength125MG/250ML (0.5MG/ML)
Dosage formEMULSION
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalNovember 2013
Marketing statusDISCN

Listed patents

PatentExpiresType
11103490October 2031product
10010537October 2031product
8658676October 2031product

More from Chiesi Usa, Inc.

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

CLEVIPREX patent cliff — loss of exclusivity October 2031 | CliffBio